<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8EB95022FE7E4DCCA53C9CB093ACA3A7" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 8976 IH: Protecting Reproductive Freedom Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-09-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8976</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220922">September 22, 2022</action-date><action-desc><sponsor name-id="R000579">Mr. Ryan of New York</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To preempt State restrictions on dispensing mifepristone or misoprostol, and for other purposes.</official-title></form><legis-body id="H8292D328F84C4892B5CB24C2B0C8417B" style="OLC"> 
<section id="HC6402F69E16141D48FD8B101CDCC6B93" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Protecting Reproductive Freedom Act</short-title></quote>.</text></section> <section id="H4E18A98DB5DB43D9AA43FCBBF80ECCB6"><enum>2.</enum><header>Preemption of State restrictions on dispensing mifepristone and misoprostol</header><text display-inline="no-display-inline">No State may establish, implement, or enforce—</text> 
<paragraph id="HC7738E8877C347B681FDD7BCA56DDDFD"><enum>(1)</enum><text>any prohibition or restriction on shipping or sending mifepristone or misoprostol across State lines;</text></paragraph> <paragraph id="HFAE1D23FA67649D58B5806B3277625BC"><enum>(2)</enum><text display-inline="yes-display-inline">any requirement that mifepristone or misoprostol be dispensed by a health care practitioner in person; or</text></paragraph> 
<paragraph id="HEDE94C35D28945C2B441A6611F399DF3"><enum>(3)</enum><text>any prohibition or restriction on prescribing or dispensing mifepristone or misoprostol by means of telehealth.</text></paragraph></section> <section id="H24AA22F97D784B5D854ECF1C2AFCD208"><enum>3.</enum><header>Report</header><text display-inline="no-display-inline">Not later than 30 days after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit a report to the Congress on ways to expand access to abortion medication.</text></section> 
<section id="HAD1C2D845DFF4846BDDA5E21D15C0A02"><enum>4.</enum><header>Definitions</header><text display-inline="no-display-inline">In this Act:</text> <paragraph id="HF6B9C5C8BBF94FCBA8F39BE380BB34CB"><enum>(1)</enum><text>The term <term>mifepristone</term> means mifepristone that is—</text> 
<subparagraph id="H894567C2191B42D38EEF68AC2A761989"><enum>(A)</enum><text>approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>);</text></subparagraph> <subparagraph id="HC1F42B40D38B42F39AE010CDD7ED6B3C"><enum>(B)</enum><text>indicated for medical abortion; and</text></subparagraph> 
<subparagraph id="HDB1D1D2417DD4EBE8CF2BFC480914A07"><enum>(C)</enum><text>subject to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>).</text></subparagraph></paragraph> <paragraph id="H957AF6FB0FA34FFAB2C97C33A09BBE67"><enum>(2)</enum><text>The term <term>misoprostol</term> means misoprostol that is—</text> 
<subparagraph id="HC3C90A9F6FE54FC594A26F56DC406A5C"><enum>(A)</enum><text>approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>);</text></subparagraph> <subparagraph id="HFACC9BDABFAE4D2DA9981D3AEFD4D3B1"><enum>(B)</enum><text>indicated for medical abortion; and</text></subparagraph> 
<subparagraph id="HE0DF0F08ADA246ACA2C9E1C690AC087E"><enum>(C)</enum><text>subject to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>).</text></subparagraph></paragraph> </section> </legis-body></bill>

